All In Biotech

Drug Trial Radar · NCT03674567

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

323

Actual

Start

Sep 25, 2018

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Sep 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab. The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.

Conditions

  • Advanced Cancer

Interventions

  • FLX475 (tivumecirnon)Drug

    tablet

  • pembrolizumab (KEYTRUDA®)Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of FLX475 as a Single Agent and in Combination With Pembrolizumab Measured by the Incidence of Adverse Events, Including Dose-limiting Toxicities and Maximum Tolerated DoseTime frame: Approximately 18 weeks
  2. Overall Response Rate in Subjects Treated With FLX475 as a Single Agent and in Combination With PembrolizumabTime frame: Through study completion (approximately 2 years)

Locations

35 sites in 6 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • City of Hope

    Duarte, California

  • University of California, Los Angeles JCCC Clinical Research Unit

    Los Angeles, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Georgetown - Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia

  • Comprehensive Hematology and Oncology, LLC

    St. Petersburg, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory Winship Cancer Institute

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • University of Louisville Hospital/James Graham Brown Cancer Center

    Louisville, Kentucky

  • Johns Hopkins University

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Quantum Santa Fe

    Santa Fe, New Mexico

  • New York Presbyterian Hospital-Columbia University Medical Center

    New York, New York

  • Carolina BioOncology Institute

    Huntersville, North Carolina

  • Mary Crowley Cancer Research Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Washington

    Seattle, Washington

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Linear Clinical Research Limited

    Nedlands, Western Australia, Australia

  • Queen Mary Hospital - Lymphoma

    High West, Hong Kong

  • Queen Mary Hospital

    High West, Hong Kong

  • Prince of Wales Hospital

    Shatin, Hong Kong

  • Chungbuk National University Hospital

    Jungbuk, South Korea

  • Seoul National University

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Chi Mei Meidcal Center

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • King Chulaongkorn Memorial Hospital

    Bangkok, Thailand

  • Ramathibodi Hospital

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.